Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active-controlled Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Bunionectomy

Next Previous
X
Search
Trial Profile

A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active-controlled Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Bunionectomy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Dec 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oliceridine (Primary) ; Morphine
  • Indications Postoperative pain
  • Focus Registrational; Therapeutic Use
  • Acronyms APOLLO-1
  • Sponsors Trevena

    • Most Recent Events

    • 08 Dec 2022 According to a Trevena media release, data from this study were presented at the American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting.
    • 10 Aug 2021 According to a Trevena media release, exploratory analysis of data from APOLLO-1 and APOLLO-2 trials with lead author Gregory B. Hammer published in the Journal of Pain and Therapy.
    • 10 Aug 2021 Exploratory analysis of data from APOLLO-1 and APOLLO-2 trials published in the Trevena Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top